{"id":"fingolimob-fty","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Liver enzyme elevation"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Macular edema"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fingolimob binds to sphingosine-1-phosphate receptors on lymphocytes, particularly S1P1, causing internalization and degradation of the receptor. This prevents lymphocyte egress from secondary lymphoid organs into the peripheral circulation, thereby reducing infiltration of autoreactive immune cells into target tissues. This mechanism is particularly effective in multiple sclerosis where it reduces relapse rates and disability progression.","oneSentence":"Fingolimob is a sphingosine-1-phosphate (S1P) receptor modulator that sequesters lymphocytes in lymphoid tissues, reducing their migration to inflamed sites.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:30.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT02769689","phase":"PHASE4","title":"Methylprednisolone During the Switch Between Natalizumab and Fingolimod","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-06-12","conditions":"Multiple Sclerosis","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"fingolimob (FTY)","genericName":"fingolimob (FTY)","companyName":"University Hospital, Clermont-Ferrand","companyId":"university-hospital-clermont-ferrand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fingolimob is a sphingosine-1-phosphate (S1P) receptor modulator that sequesters lymphocytes in lymphoid tissues, reducing their migration to inflamed sites. Used for Relapsing-remitting multiple sclerosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}